BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 30558603)

  • 1. Early venous thromboembolism at the beginning of palliative chemotherapy is a poor prognostic factor in patients with metastatic pancreatic cancer: a retrospective study.
    Kim JS; Kang EJ; Kim DS; Choi YJ; Lee SY; Kim HJ; Seo HY; Kim JS
    BMC Cancer; 2018 Dec; 18(1):1260. PubMed ID: 30558603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early detection of venous thromboembolism after the initiation of chemotherapy predicts a poor prognosis in patients with unresectable metastatic pancreatic cancer who underwent first-line chemotherapy with gemcitabine plus nab-paclitaxel.
    Yamai T; Ikezawa K; Hiraga E; Kawamoto Y; Hirao T; Higashi S; Daiku K; Maeda S; Abe Y; Urabe M; Kai Y; Takada R; Nakabori T; Fukutake N; Uehara H; Fujita M; Ohkawa K
    PLoS One; 2022; 17(3):e0264653. PubMed ID: 35231078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence, outcome and risk stratification tools for venous thromboembolism in advanced pancreatic cancer - A retrospective cohort study.
    Kruger S; Haas M; Burkl C; Goehring P; Kleespies A; Roeder F; Gallmeier E; Ormanns S; Westphalen CB; Heinemann V; Rank A; Boeck S
    Thromb Res; 2017 Sep; 157():9-15. PubMed ID: 28675831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Khorana Score in Predicting Venous Thromboembolism for Patients With Metastatic Urothelial Carcinoma and Variant Histology Treated With Chemotherapy.
    Ramos JD; Casey MF; Bamias A; De Giorgi U; Bellmunt J; Harshman LC; Ladoire S; Wong YN; Alva AS; Rosenberg JE; Galsky MD; Yu EY;
    Clin Appl Thromb Hemost; 2017 Oct; 23(7):755-760. PubMed ID: 27637910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel.
    Riedl JM; Schwarzenbacher E; Moik F; Horvath L; Gantschnigg A; Renneberg F; Posch F; Barth DA; Stotz M; Pichler M; Hatzl S; Fandler-Höfler S; Gressenberger P; Gary T; Jost PJ; Greil R; Ay C; Djanani A; Gerger A; Schlick K
    Thromb Haemost; 2022 Apr; 122(4):633-645. PubMed ID: 34255340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venous Thromboembolism in Patients with Advanced Pancreatic Cancer Receiving Palliative Chemotherapy: Incidence and Effect on Prognosis.
    Jeong HT; Bae JH; Kim HG; Han J
    Korean J Gastroenterol; 2023 Mar; 81(3):109-120. PubMed ID: 36960693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of venous thromboembolism (VTE) in ambulatory pancreatic cancer patients receiving chemotherapy and analysis of Khorana's predictive model.
    Muñoz Martín AJ; García Alfonso P; Rupérez Blanco AB; Pérez Ramírez S; Blanco Codesido M; Martín Jiménez M
    Clin Transl Oncol; 2014 Oct; 16(10):927-30. PubMed ID: 24643701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemostatic Biomarkers and Venous Thromboembolism Are Associated With Mortality and Response to Chemotherapy in Patients With Pancreatic Cancer.
    Moik F; Prager G; Thaler J; Posch F; Wiedemann S; Schramm T; Englisch C; Mackman N; Pabinger I; Ay C
    Arterioscler Thromb Vasc Biol; 2021 Nov; 41(11):2837-2847. PubMed ID: 34470475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Khorana score for the prediction of venous thromboembolism in patients with pancreatic cancer.
    van Es N; Franke VF; Middeldorp S; Wilmink JW; Büller HR
    Thromb Res; 2017 Feb; 150():30-32. PubMed ID: 28002757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prognostic index model to predict the clinical outcomes for advanced pancreatic cancer patients following palliative chemotherapy.
    Xue P; Zhu L; Wan Z; Huang W; Li N; Chen D; Hu J; Yang H; Wang L
    J Cancer Res Clin Oncol; 2015 Sep; 141(9):1653-60. PubMed ID: 25792009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer.
    Maraveyas A; Waters J; Roy R; Fyfe D; Propper D; Lofts F; Sgouros J; Gardiner E; Wedgwood K; Ettelaie C; Bozas G
    Eur J Cancer; 2012 Jun; 48(9):1283-92. PubMed ID: 22100906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk stratification for the development of venous thromboembolism in hospitalized patients with cancer.
    Parker A; Peterson E; Lee AYY; de Wit C; Carrier M; Polley G; Tien J; Wu C
    J Thromb Haemost; 2018 Jul; 16(7):1321-1326. PubMed ID: 29733498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simple prognostic markers for optimal treatment of patients with unresectable pancreatic cancer.
    Terao T; Kumagi T; Hyodo I; Yokota T; Azemoto N; Miyata H; Kuroda T; Ohno Y; Tanaka Y; Shibata N; Imamura Y; Kanemitsu K; Miyake T; Koizumi M; Hiasa Y;
    Medicine (Baltimore); 2021 Oct; 100(43):e27591. PubMed ID: 34713835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy-induced neutropenia as a prognostic factor in patients with metastatic pancreatic cancer treated with gemcitabine.
    Otake A; Tsuji D; Taku K; Kawasaki Y; Yokoi M; Nakamori H; Osada M; Matsumoto M; Inoue K; Hirai K; Itoh K
    Eur J Clin Pharmacol; 2017 Aug; 73(8):1033-1039. PubMed ID: 28487999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ADAMTS-13 and von Willebrand factor predict venous thromboembolism in patients with cancer.
    Pépin M; Kleinjan A; Hajage D; Büller HR; Di Nisio M; Kamphuisen PW; Salomon L; Veyradier A; Stepanian A; Mahé I
    J Thromb Haemost; 2016 Feb; 14(2):306-15. PubMed ID: 26589836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival.
    Ramos JD; Casey MF; Crabb SJ; Bamias A; Harshman LC; Wong YN; Bellmunt J; De Giorgi U; Ladoire S; Powles T; Pal SK; Niegisch G; Recine F; Alva A; Agarwal N; Necchi A; Vaishampayan UN; Rosenberg JE; Galsky MD; Yu EY;
    Cancer Med; 2017 Jan; 6(1):186-194. PubMed ID: 28000388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early venous thromboembolism is a strong prognostic factor in patients with advanced pancreatic ductal adenocarcinoma.
    Barrau M; Maoui K; Le Roy B; Roblin X; Mismetti P; Phelip JM; Williet N
    J Cancer Res Clin Oncol; 2021 Nov; 147(11):3447-3454. PubMed ID: 33715087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation and application of a prognostic model for patients with advanced pancreatic cancer receiving palliative chemotherapy.
    Huang PW; Chang CF; Hung CY; Hsueh SW; Chang PH; Yeh KY; Chen JS; Chen YY; Lu CH; Hung YS; Chou WC
    Cancer Med; 2019 Sep; 8(12):5554-5563. PubMed ID: 31385456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of Khorana Risk Score for Prediction of Venous Thromboembolism in Patients With Hepatocellular Carcinoma.
    Wang Y; Attar BM; Fuentes HE; Yu J; Zhang H; Tafur AJ
    Clin Appl Thromb Hemost; 2018 Apr; 24(3):471-476. PubMed ID: 28288526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for cancer-associated venous thromboembolism: The venous thromboembolism prevention in the ambulatory cancer clinic (VTE-PACC) study.
    Douce DR; Holmes CE; Cushman M; MacLean CD; Ades S; Zakai NA
    J Thromb Haemost; 2019 Dec; 17(12):2152-2159. PubMed ID: 31423717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.